QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=A8AB09FA390A3AE4E0D1D6F38BF237B8;jsessionid=51586F57457820B19218871CCD1B1B0A;jsessionid=1378266A38B81A4711AC8DCC93F77B7F;jsessionid=73AC8971AD1AC6EB5D00E04011873BA7;jsessionid=C057DE3D41D9400A19D1CA708AC75D4C;jsessionid=CE2049D0E55AC0DF318C4A9DF0DF865C;jsessionid=40D63FBCCF5DFB4A3E0691C49BF4573F;jsessionid=60D81DDFE4CEECDA1FB7BA152962B2A8;jsessionid=55771DBD3D7F9EE24E81D064BE8D88CC;jsessionid=ED5F2549F138BF4B2E0B31E563ED6E69;jsessionid=992D8CA3CB7F01FA453D25459BB76347;jsessionid=91264C719FDF12D3DAFB4F8D961CDD9D (gene)

1. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
2. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…
3. The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissue…
4. Ataxin-2 gene: a powerful modulator of neurological disorders.
5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=A8AB09FA390A3AE4E0D1D6F38BF237B8;jsessionid=51586F57457820B19218871CCD1B1B0A;jsessionid=1378266A38B81A4711AC8DCC93F77B7F;jsessionid=73AC8971AD1AC6EB5D00E04011873BA7;jsessionid=C057DE3D41D9400A19D1CA708AC75D4C;jsessionid=CE2049D0E55AC0DF318C4A9DF0DF865C;jsessionid=40D63FBCCF5DFB4A3E0691C49BF4573F;jsessionid=60D81DDFE4CEECDA1FB7BA152962B2A8;jsessionid=55771DBD3D7F9EE24E81D064BE8D88CC;jsessionid=ED5F2549F138BF4B2E0B31E563ED6E69;jsessionid=992D8CA3CB7F01FA453D25459BB76347;jsessionid=91264C719FDF12D3DAFB4F8D961CDD9D